argenx SE (EBR:ARGX)
471.10
-2.10 (-0.44%)
Jun 20, 2025, 5:35 PM CET
argenx SE Revenue
argenx SE had revenue of $807.37M USD in the quarter ending March 31, 2025, with 95.72% growth. This brings the company's revenue in the last twelve months to $2.64B, up 82.13% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.22% growth.
Revenue (ttm)
$2.64B
Revenue Growth
+82.13%
P/S Ratio
11.76
Revenue / Employee
$1.65M
Employees
1,599
Market Cap
28.77B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UCB SA | 6.15B |
Financière de Tubize | 13.26K |
Fagron NV | 871.96M |
Ion Beam Applications | 498.16M |
Nyxoah | 4.36M |
Onward Medical | 1.74M |
Hyloris Pharmaceuticals | 9.76M |
Sequana Medical NV | 105.50K |
argenx SE News
- 9 hours ago - argenx gets EU nod for Vyvgart subcutaneous injection - Seeking Alpha
- 10 hours ago - argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewsWire
- 4 days ago - $1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga
- 10 days ago - argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease - Benzinga
- 10 days ago - argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease - GlobeNewsWire
- 17 days ago - argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 23 days ago - argenx Announces Results of Annual General Meeting of Shareholders - GlobeNewsWire
- 4 weeks ago - Hot Picks in biotech: argenx, Scholar Rock & Kiniksa - BNN Bloomberg